New applications of CRISPR/Cas9 system on mutant DNA detection

Gene. 2018 Jan 30:641:55-62. doi: 10.1016/j.gene.2017.10.023. Epub 2017 Oct 12.

Abstract

The detection of mutant DNA is critical for precision medicine, but low-frequency DNA mutation is very hard to be determined. CRISPR/Cas9 is a robust tool for in vivo gene editing, and shows the potential for precise in vitro DNA cleavage. Here we developed a DNA mutation detection system based on CRISPR/Cas9 that can detect gene mutation efficiently even in a low-frequency condition. The system of CRISPR/Cas9 cleavage in vitro showed a high accuracy similar to traditional T7 endonuclease I (T7E1) assay in estimating mutant DNA proportion in the condition of normal frequency. The technology was further used for low-frequency mutant DNA detection of EGFR and HBB somatic mutations. To the end, Cas9 was employed to cleave the wild-type (WT) DNA and to enrich the mutant DNA. Using amplified fragment length polymorphism analysis (AFLPA) and Sanger sequencing, we assessed the sensitivity of CRISPR/Cas9 cleavage-based PCR, in which mutations at 1%-10% could be enriched and detected. When combined with blocker PCR, its sensitivity reached up to 0.1%. Our results suggested that this new application of CRISPR/Cas9 system is a robust and potential method for heterogeneous specimens in the clinical diagnosis and treatment management.

Keywords: Blocker; CRISPR/Cas9; Mutation detection; Mutation enrichment.

MeSH terms

  • Amplified Fragment Length Polymorphism Analysis
  • CRISPR-Cas Systems / genetics*
  • Carcinoma, Non-Small-Cell Lung
  • DNA / analysis*
  • DNA / genetics
  • Deoxyribonuclease I / genetics
  • ErbB Receptors / genetics*
  • HEK293 Cells
  • Hemoglobin Subunits / genetics*
  • Humans
  • Lung Neoplasms
  • Mutation / genetics
  • Mutation Rate
  • Polymerase Chain Reaction / methods*
  • Tumor Cells, Cultured

Substances

  • Hemoglobin Subunits
  • DNA
  • EGFR protein, human
  • ErbB Receptors
  • Deoxyribonuclease I